Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
98 hedge funds and large institutions have $131M invested in Catalyst Pharmaceutical in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 42 increasing their positions, 19 reducing their positions, and 25 closing their positions.
121% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 19
1.34% less ownership
Funds ownership: 54.7% → 53.36% (-1.3%)
7% less funds holding
Funds holding: 105 → 98 (-7)
23% less call options, than puts
Call options by funds: $60K | Put options by funds: $78K
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
40% less capital invested
Capital invested by funds: $219M → $131M (-$88.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$2.66M |
| 2 |
BlackRock
New York
|
+$2.26M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.94M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$1.73M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.89M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.81M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.73M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$3.09M |
| 5 |
Millennium Management
New York
|
-$2.28M |
CPRX Hedge Fund Activity: Q1 2018 in Review
98 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2018, worth a combined $131M — down 40% from $219M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CPRX and 18 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 42 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $2.66M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.89M.
- 98 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2018, down from 105 in Q4 2017.
- Funds reported $131M of Catalyst Pharmaceutical stock for Q1 2018, down 40% quarter-over-quarter.
- 18 funds opened new Catalyst Pharmaceutical positions in Q1 2018 and 25 closed out, a net change of -7 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2018 was Avoro Capital Advisors, an estimated $2.66M added.
- The largest Catalyst Pharmaceutical seller in Q1 2018 was Baker Bros. Advisors, an estimated $4.89M sold.
Based on aggregated 13F filings for Q1 2018.